Format

Send to

Choose Destination
Ann Biol Clin (Paris). 2014 Jul-Aug;72(4):391-404. doi: 10.1684/abc.2014.0968.

[Triazole antifungal agents: practice guidelines of therapeutic drug monitoring and perspectives in treatment optimization].

[Article in French]

Author information

1
Service de pharmacocinétique et toxicologie, Laboratoire de biologie médicale, Assistance Publique - Hôpitaux de Marseille (AP-HM), Hôpital de la Timone, Marseille, France.

Abstract

Antifungal triazole agents (fluconazole, voriconazole, itraconazole and posaconazole) are widely used for the management of invasive fungal infections (IFI). These drugs are indicated both for the prophylaxis and treatment of IFI, particularly in candidiasis and aspergillosis, major cause of mortality in immunocompromised patients. Due to a large interindividual pharmacokinetic variability leading to sub-therapeutic or toxic concentrations and to concentration-efficacy and/or -toxicity relationships, therapeutic drug monitoring (TDM) of antifungal triazole is fully justified. This review provides an overview of literature based data that confirm the usefulness of such TDM and its level of evidence as well as the practical guidelines for its implementation. In addition, we discuss the interest of new tools to improve the clinical management of IFI, such as genotyping tests optimizing initial voriconazole dosing regimen or the development of a new solid oral tablet of posaconazole improving its bioavailability and limiting absorption disorders.

KEYWORDS:

interindividual variability; pharmacokinetic; therapeutic drug monitoring; triazole antifungal

PMID:
25119797
DOI:
10.1684/abc.2014.0968
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for John Libbey Eurotext
Loading ...
Support Center